102 related articles for article (PubMed ID: 28129977)
1. Synthesis of cholesteryl doxorubicin and its anti-cancer activity.
Choi JS; Doh KO; Kim BK; Seu YB
Bioorg Med Chem Lett; 2017 Feb; 27(4):723-728. PubMed ID: 28129977
[TBL] [Abstract][Full Text] [Related]
2. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.
Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC
J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
4. Application of Coiled Coil Peptides in Liposomal Anticancer Drug Delivery Using a Zebrafish Xenograft Model.
Yang J; Shimada Y; Olsthoorn RC; Snaar-Jagalska BE; Spaink HP; Kros A
ACS Nano; 2016 Aug; 10(8):7428-35. PubMed ID: 27504667
[TBL] [Abstract][Full Text] [Related]
5. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.
Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW
Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644
[TBL] [Abstract][Full Text] [Related]
9. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
Zhang ZQ; Zhong CL; Zhao X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
[TBL] [Abstract][Full Text] [Related]
10. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
11. Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.
Wang W; Shao A; Zhang N; Fang J; Ruan JJ; Ruan BH
Sci Rep; 2017 Feb; 7():43036. PubMed ID: 28225062
[TBL] [Abstract][Full Text] [Related]
12. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
[TBL] [Abstract][Full Text] [Related]
13. Thermosensitive magnetic liposomes with doxorubicin cell-penetrating peptides conjugate for enhanced and targeted cancer therapy.
Lin W; Xie X; Yang Y; Fu X; Liu H; Yang Y; Deng J
Drug Deliv; 2016 Nov; 23(9):3436-3443. PubMed ID: 27193383
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
15. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity analysis of doxorubicin-loaded/superparamagnetic iron oxide colloidal nanoassemblies on MCF7 and NIH3T3 cell lines.
Tomankova K; Polakova K; Pizova K; Binder S; Havrdova M; Kolarova M; Kriegova E; Zapletalova J; Malina L; Horakova J; Malohlava J; Kolokithas-Ntoukas A; Bakandritsos A; Kolarova H; Zboril R
Int J Nanomedicine; 2015; 10():949-61. PubMed ID: 25673990
[TBL] [Abstract][Full Text] [Related]
17. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
18. Application of liposomes incorporating doxorubicin with sialyl Lewis X to prevent stenosis after rat carotid artery injury.
Tsuruta W; Tsurushima H; Yamamoto T; Suzuki K; Yamazaki N; Matsumura A
Biomaterials; 2009 Jan; 30(1):118-25. PubMed ID: 18842296
[TBL] [Abstract][Full Text] [Related]
19. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
